期刊文献+

非小细胞肺癌术后放射治疗疗效影响因素 被引量:1

The Effect of Postoperative Radiotherapy for Non-small Cell Lung Cancer
暂未订购
导出
摘要 [目的]分析非小细胞肺癌术后的放射治疗影响因素。[方法]对1989年4月~1996年7月收治的非小细胞肺癌术后214例 ,接受 60Co或8MVX线放疗 ,肿瘤量为40Gy~70Gy。用Cox单因素和多因素回归分析法分析影响术后放疗疗效的因素。[结果]3、5年生存率32.00 %、21.03% ;复发率42.00%、70.09%。鳞癌患者生存率高于腺癌者 (P<0.01) ,复发率则低于腺癌者 (P<0.05)。当T1~2 时N0~1 比N2~3 生存率高 (P<0.01) ,当T3~4 时 (P<0.05)。肿瘤有残留者生存率差于切缘阳性者和/或局部淋巴结阳性 ,且复发率高 (P<0.01)。照射剂量≥50Gy者生存率高于<50Gy者 ,而复发率低 (P<0.05)。性别、年龄、术后时间不影响预后。[结论]肺癌术后的放疗影响生存率 ,复发率的主要因素为病理类型、术后残留情况。 To analysis the effect of radiotherapy in patients with non small cell lung cancer after operation .Two hundred anel fourteen patients with non_small cell lung cancer were treated in our hospital from April 1989 to July 1996.They had a radiotherapy with 8MV X line or 60Co whose tumor dose was 40Gy~70Gy.Cox regression model were used to analysis the factors which influence therapeutic effect in 214 patient.The survival rate of 3 and 5 years was 32.00% and 21.03% respectively.The recurrent rate of 3 and 5 years was 42.00% and 70.09% respectively.Patients with squamous cancer had a better survival rate(P<0.01)and less recurrent rate than patients with adenocarcinoma cancer (P<0.05).Better survival rate in patients with N0~1than those in patients with N2~ 3was found.Patients with residual tumor had a worse survival rate and less recurrence rate than those with positive wargin or with positive nodes (P<0.01).Patients who received radiotherapy with DT ≥50Gy had a better survival rate and less recurrent rate than those with DT<50Gy.Sex,age and postoperative time did not affect the prognosis.[Conclusions]Pathologic type,residual tumor,positive margin and the dose (P<0.05)of radiation are the affected factors to survival and recurrence in non small cell lung cancer.
机构地区 福建省肿瘤医院
出处 《肿瘤学杂志》 CAS 2001年第6期359-360,共2页 Journal of Chinese Oncology
关键词 非小细胞肺癌 放射疗法 外科学 预后 治疗 non small cell lung cancer radiotherapy surgery prognosis efficacy
  • 相关文献

参考文献3

二级参考文献16

  • 1陈东福,殷蔚伯,杨宗贻,张志贤,苗延浚,汪楣,张宏兴,谷铣之.非小细胞肺癌姑息术后放疗108例[J].中华放射肿瘤学杂志,1992,0(2):18-20. 被引量:11
  • 2Noah C.Controversies in the role of postoperative radiotherapy in stages Ⅱ and Ⅲa resected non-small cell lung carcinoma. International Journal of Radiation Oncology Biology Physics . 1991
  • 3Chung MD.Evaluation of adjuvant postoperative radiotherapy for lung cancer. International Journal of Radiation Oncology Biology Physics . 1982
  • 4Clemente I.local Recurrence of resectable non-oat cell carcinoma or the lung. Cancer . 1986
  • 5Belcher JR.Thirty years of surgery for carcinoma of bronchus. Thorax . 1983
  • 6Jerry D.Radiation therapy following resection of non small cell lung cancer. International Journal of Radiation Oncology Biology Physics . 1991
  • 7JohnsonDH,TurrisiAT,ChanpAY,et al.Alternatingchemotherapy and twice daily thoracic radiotherapy inlimited- stage small cell lung cancer:A plotstudy of theEasternCooperativeOncologyGroup. JClinOncol . 1993
  • 8SugarbakerDJ,StraussGM.Advances in surgical stagingand therapy of non- small cell lung cancer. Seminars in Oncology . 1993
  • 9PerryMC,EatonWL,ChaninianP,et al.Chemothera-py with or without radiotherapy in limited small cell car-cinoma of the lung. The New England Journal of Medicine . 1987
  • 10MackMT,AronoffRT,AcuffTE,etal.Presentrole ofthoracoscopy in the diagnosis and treatment of disease ofthe chest. The Annals of Thoracic Surgery . 1992

共引文献25

同被引文献14

  • 1Harari PM, Huang SM. Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. Semin Radiat Oncol,2002, 12(Suppl 2): 21-26.
  • 2Tang Z, Du R, Jiang S, et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer, 2008,99(6): 911-922.
  • 3Das AK, Chen BP, Story MD, et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res, 2007,67(11): 5267-5274.
  • 4Safe S, Papineni S, Chintharlapalli S. Cancer chemotherapy with indole-3- carbinol, bis (3'-indolyl) methane and synthetic analogs. Cancer Lett, 2008, 269(2): 326-338.
  • 5Mao Y, Wu J, Skog S, et al. Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and eDNA profiling. Oncol Rep, 2005,13(5): 837-846.
  • 6Kim YH, Ishii G, Goto K, et al. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer, 2009, 65( 1): 105-111.
  • 7Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in nonsmall-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One, 2009, 4( 5): e5133.
  • 8Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One, 2008,3(11): e3695.
  • 9Wang L, Wei], Qian X, et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/ or docetaxel. BMC Cancer, 2008, 8: 97-100.
  • 10Wachters FM, Wong LS, Timens WK, et al. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer, 2005, 50(2): 211-219.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部